CHINA PHARMA HOLDINGS, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
CHINA PHARMA HOLDINGS, INC. (CPHI) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$593.03 thousand for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2023-08-14
- CHINA PHARMA HOLDINGS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2023-06-30 was -$593.03K.
- CHINA PHARMA HOLDINGS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2023-03-31 was -$475.98K.
- CHINA PHARMA HOLDINGS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2022-06-30 was -$888.39K.
- CHINA PHARMA HOLDINGS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2022-03-31 was -$1.03M.
- CHINA PHARMA HOLDINGS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$3.97M.
- CHINA PHARMA HOLDINGS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2021 was -$3.40M.
- CHINA PHARMA HOLDINGS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2020 was -$2.87M.
- CHINA PHARMA HOLDINGS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2014 was -$39.55M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2023-06-30 | -$593.03K 10-Q · filed 2023-08-14 | -$1.07M derived: sum of 2 quarters · filed 2023-08-14 | ||||||
| 2023-03-31 | -$475.98K 10-Q · filed 2023-08-14 | |||||||
| 2022-12-31 | -$3.97M 10-K · filed 2023-03-30 | |||||||
| 2022-06-30 | -$888.39K 10-Q · filed 2023-08-14 | -$1.92M derived: sum of 2 quarters · filed 2023-08-14 | ||||||
| 2022-03-31 | -$1.03M 10-Q · filed 2023-08-14 | |||||||
| 2021-12-31 | -$3.40M 10-K · filed 2023-03-30 | |||||||
| 2021-09-30 | -$826.67K 10-Q · filed 2021-11-12 | -$1.65M derived: sum of 2 quarters · filed 2021-11-12 | -$2.42M derived: sum of 3 quarters · filed 2022-05-12 | |||||
| 2021-06-30 | -$824.76K 10-Q · filed 2021-11-12 | -$1.59M derived: sum of 2 quarters · filed 2022-05-12 | ||||||
| 2021-03-31 | -$767.33K 10-Q · filed 2022-05-12 | |||||||
| 2020-12-31 | -$2.87M 10-K · filed 2022-03-30 | |||||||
| 2020-09-30 | -$1.01M 10-Q · filed 2021-11-12 | -$996.84K derived: sum of 2 quarters · filed 2021-11-12 | -$1.66M derived: sum of 3 quarters · filed 2021-11-12 | |||||
| 2020-06-30 | $13.05K 10-Q · filed 2021-11-12 | -$647.84K derived: sum of 2 quarters · filed 2021-11-12 | ||||||
| 2020-03-31 | -$660.90K 10-Q · filed 2021-11-12 | |||||||
| 2019-09-30 | -$700.95K 10-Q · filed 2019-11-14 | -$1.54M derived: sum of 2 quarters · filed 2019-11-14 | -$1.96M derived: sum of 3 quarters · filed 2019-11-14 | |||||
| 2019-06-30 | -$838.10K 10-Q · filed 2019-11-14 | -$1.26M derived: sum of 2 quarters · filed 2019-11-14 | ||||||
| 2019-03-31 | -$417.73K 10-Q · filed 2019-11-14 | |||||||
| 2018-09-30 | -$1.86M 10-Q · filed 2019-11-14 | -$2.86M derived: sum of 2 quarters · filed 2019-11-14 | -$3.16M derived: sum of 3 quarters · filed 2019-11-14 | |||||
| 2018-06-30 | -$1.01M 10-Q · filed 2019-11-14 | -$1.30M derived: sum of 2 quarters · filed 2019-11-14 | ||||||
| 2018-03-31 | -$293.48K 10-Q · filed 2019-11-14 | |||||||
| 2017-09-30 | -$2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | -$4.48M derived: sum of 2 quarters · filed 2017-11-14 | -$5.45M 10-Q · filed 2017-11-14 | |||||
| 2017-06-30 | -$2.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | -$3.25M 10-Q · filed 2017-08-14 | ||||||
| 2017-03-31 | -$966.90K 10-Q · filed 2018-05-14 | |||||||
| 2016-09-30 | -$1.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | -$4.20M derived: sum of 2 quarters · filed 2017-11-14 | -$5.76M 10-Q · filed 2017-11-14 | |||||
| 2016-06-30 | -$2.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | -$4.01M 10-Q · filed 2017-08-14 | ||||||
| 2016-03-31 | -$1.55M 10-Q · filed 2017-05-11 | |||||||
| 2015-09-30 | -$2.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-12-28 | -$6.43M derived: sum of 2 quarters · filed 2015-12-28 | -$9.16M 10-Q · filed 2015-12-28 | -$16.24M 10-Q · filed 2015-11-16 | -$32.69M derived: sum of 4 quarters · filed 2016-05-16 | |||
| 2015-06-30 | -$4.12M 10-Q · filed 2015-08-14 | -$6.85M 10-Q · filed 2016-08-11 | -$12.09M 10-Q · filed 2015-08-14 | -$30.37M derived: sum of 3 quarters · filed 2016-05-16 | -$36.70M derived: sum of 4 quarters · filed 2016-05-16 | |||
| 2015-03-31 | -$4.07M 10-Q · filed 2016-05-16 | -$7.97M 10-Q · filed 2015-05-11 | -$26.26M derived: sum of 2 quarters · filed 2016-05-16 | -$32.59M derived: sum of 3 quarters · filed 2016-05-16 | -$41.23M derived: sum of 4 quarters · filed 2016-05-16 | |||
| 2014-12-31 | -$22.19M derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-28 | -$28.52M derived: sum of 2 quarters · filed 2015-12-28 | -$37.16M derived: sum of 3 quarters · filed 2015-12-28 | -$39.55M 10-K · filed 2015-12-28 | -$26.05M 10-K · filed 2015-03-30 | |||
| 2014-09-30 | -$6.33M 10-Q · filed 2014-11-14 | -$14.97M derived: sum of 2 quarters · filed 2015-08-14 | -$17.36M 10-Q · filed 2015-12-28 | -$27.79M derived: sum of 4 quarters · filed 2015-12-28 | ||||
| 2014-06-30 | -$8.64M 10-Q · filed 2015-08-14 | -$11.03M 10-Q · filed 2015-12-28 | -$21.46M derived: sum of 3 quarters · filed 2015-12-28 | -$23.77M derived: sum of 4 quarters · filed 2015-12-28 | ||||
| 2014-03-31 | -$2.39M 10-Q · filed 2015-12-28 | -$12.82M derived: sum of 2 quarters · filed 2015-12-28 | -$15.12M derived: sum of 3 quarters · filed 2015-12-28 | -$19.59M derived: sum of 4 quarters · filed 2015-12-28 | ||||
| 2013-12-31 | -$10.43M derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-28 | -$12.73M derived: sum of 2 quarters · filed 2015-12-28 | -$17.20M derived: sum of 3 quarters · filed 2015-12-28 | -$20.01M 10-K · filed 2015-12-28 | ||||
| 2013-09-30 | -$2.30M 10-Q · filed 2014-11-14 | -$6.77M derived: sum of 2 quarters · filed 2014-11-14 | -$9.58M 10-Q · filed 2014-11-14 | -$10.82M derived: sum of 4 quarters · filed 2014-11-14 | ||||
| 2013-06-30 | -$4.46M 10-Q · filed 2014-08-14 | -$7.28M 10-Q · filed 2014-08-14 | -$8.52M derived: sum of 3 quarters · filed 2014-08-14 | -$7.22M derived: sum of 4 quarters · filed 2014-08-14 | ||||
| 2013-03-31 | -$2.81M 10-Q · filed 2014-05-15 | $2.81M 10-Q · filed 2013-05-14 | -$4.06M derived: sum of 2 quarters · filed 2014-05-15 | -$2.76M derived: sum of 3 quarters · filed 2014-05-15 | -$1.00M derived: sum of 4 quarters · filed 2014-05-15 | |||
| 2012-12-31 | -$1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-20 | $51.38K derived: sum of 2 quarters · filed 2014-03-20 | $1.81M derived: sum of 3 quarters · filed 2014-03-20 | $4.62M 10-K · filed 2014-03-20 | ||||
| 2012-09-30 | $1.30M 10-Q · filed 2013-11-14 | $3.06M derived: sum of 2 quarters · filed 2013-11-14 | $5.86M 10-Q · filed 2013-11-14 | $9.98M derived: sum of 4 quarters · filed 2013-11-14 | ||||
| 2012-06-30 | $1.76M 10-Q · filed 2013-08-14 | $4.57M 10-Q · filed 2013-08-14 | $8.69M derived: sum of 3 quarters · filed 2013-08-14 | $13.66M derived: sum of 4 quarters · filed 2013-08-14 | ||||
| 2012-03-31 | $2.81M 10-Q · filed 2013-05-14 | $6.93M derived: sum of 2 quarters · filed 2013-05-14 | $11.90M derived: sum of 3 quarters · filed 2013-05-14 | $16.97M derived: sum of 4 quarters · filed 2013-05-14 | ||||
| 2011-12-31 | $4.12M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-14 | $9.10M derived: sum of 2 quarters · filed 2013-03-14 | $14.17M derived: sum of 3 quarters · filed 2013-03-14 | $19.27M 10-K · filed 2013-03-14 | ||||
| 2011-09-30 | $4.97M 10-Q · filed 2012-11-14 | $10.04M derived: sum of 2 quarters · filed 2012-11-14 | $15.15M 10-Q · filed 2012-11-14 | $13.46M 10-Q · filed 2011-11-10 | $21.71M derived: sum of 4 quarters · filed 2012-11-14 | |||
| 2011-06-30 | $5.07M 10-Q · filed 2012-08-14 | $10.17M 10-Q · filed 2012-08-14 | $16.74M derived: sum of 3 quarters · filed 2012-08-14 | $22.65M derived: sum of 4 quarters · filed 2012-08-14 | ||||
| 2011-03-31 | $5.10M 10-Q · filed 2012-05-14 | $11.67M derived: sum of 2 quarters · filed 2012-05-14 | $17.58M derived: sum of 3 quarters · filed 2012-05-14 | |||||
| 2010-12-31 | $6.56M derived: 10-K 12 month − 10-Q/A 9 month · filed 2012-03-14 | $12.48M derived: sum of 2 quarters · filed 2012-03-14 | $23.41M 10-K · filed 2012-03-14 | |||||
| 2010-09-30 | $5.91M 10-Q/A · filed 2012-03-06 | $16.85M 10-Q/A · filed 2012-03-06 | ||||||
| 2010-06-30 | $10.94M 10-Q/A · filed 2011-09-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |